The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
|Videos|November 21, 2017
Dr. Pant Discusses the Current Treatment Landscape of CRC
Author(s)Shubham Pant, MD, MBBS
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.
Advertisement
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer (CRC).
Patients with CRC need more options, says Pant. In a disease with a high varitey of mutations, treatments need to be developed in order to find the optimal therapy for each patient population.
Advertisement
Related to this article
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
5